Title: RETROSPECTIVE STUDY TO ASSESS AXILLARY MANAGEMENT AND ONCOLOGICAL OUTCOME AFTER NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER PATIENTS

Biography:

Abstract

Preoperative chemotherapy (NAC) has been recognized as the   standard of care for patients with locally advanced breast cancer and recently some patients with stage 2 and chemoresponsive subtypes ( HER2 , TNBC). Lymph node status is the most important prognostic factor in patients who receive neoadjuvant therapy.Patients who have a positive lymph node by fine-needle aspiration (or core needle biopsy) before neoadjuvant therapy usually undergo completion axillary dissection at the time of primary tumor resection.ALND has been the standard treatment of the axilla after NAC for many years.SLNB as an alternative can reduce the extent of axillary surgery without compromising the prognostic and predictive value of axillary staging.